<DOC>
	<DOCNO>NCT00269022</DOCNO>
	<brief_summary>Despite success triptan class drug , approximately 60 % patient take medication moderate severe pain stage acute migraine , still pain mild great degree 2 hr post dose . SB-705498 novel , first class TRPV1 receptor antagonist development treatment migraine pain . Preclinical experiment demonstrate TRPV1 receptor express centrally peripherally trigeminal system inhibition TRPV1 SB-705498 prevent reverse establish central sensitisation .</brief_summary>
	<brief_title>Use Of SB-705498 In The Acute Treatment Of Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Inclusion criterion : Healthy subject suffer moderate severe migraine headache without aura . Women child bear potential must use effective method contraception . Have least 1 year history migraine age onset prior 50 year . Suffering 1 6 migraine attack per month least last 3 month least 48 hour free headache migraine attack . Exclusion criterion : Headache 15 days/month great three month ( 90 day ) precede entry study . Use migraine medication ( e.g. , ergotamine , triptan , opioid , combination medication ) &gt; /= 10 day per month regular basis &gt; /= 3 month . Use analgesic &gt; /=15 day per month &gt; /=3 month , use opiate ( except codeine ) first line treatment migraine . Migraine symptoms respond triptan drug ( e.g. , Imitrex , Relpax , Maxalt ) . Have uncontrolled hypertension history/ presence multiple cardiovascular risk factor , limited family history , myocardial infarction , coronary artery disease , vasospastic angina , heart failure , cardiac arrhythmia history presence cerebrovascular disease , include transient ischemic attack , stroke peripheral arterial disease . History alcohol , substance drug abuse within last year . Participation trial new chemical entity within 3 month start study . Participation research trial within 30 day prior first dose current study medication permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>SB-705498 acute migraine single dose TRPV1 combination inpatient outpatient study</keyword>
</DOC>